Treatment of MAS, or the bête noire in Still's disease, presented at the Plenary session by Peter Nigrovic #Plenary ro

Tweet Author

Tweet Content

Treatment of MAS, or the bête noire in Still's disease, presented at the Plenary session by Peter Nigrovic #Plenary room #EULAR2025 @RheumNow https://t.co/S4SG2VflNg

Links

https://x.com/Nellziade/status/1932782578127213021/photo/1

#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources, #Easylupus is

Tweet Author

bella_mehta

Tweet Content

#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources, #Easylupus is condensed, even more easy to read It's better to ask your patients to use it as a reliable source! #EULAR2025 @RheumNow https://t.co/FbYYm1dB8E

Links

https://x.com/bella_mehta/status/1932783467500351862/photo/1

Debuting Fishbowl sessions at #EULAR2025 🔄💊 Lively audience engaging session in A1 on how drug prices influence t

Tweet Author

JihaRheum

Tweet Content

Debuting Fishbowl sessions at #EULAR2025 🔄💊 Lively audience engaging session in A1 on how drug prices influence treatment decisions; real-world tensions between cost, access, & physician autonomy. Transparent, interactive, and packed! @RheumNow | Location: A1 | #EULAR2025 https://t.co/jVbviLuTZK

Links

https://x.com/JihaRheum/status/1932775698814402848/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Tweet Author

RheumNow

Tweet Content

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

#MTX in new #PMR?! RCT of #MTX was negative in early #PMR - no effect on #steroid #tapering ACR24 #1697 At #EULAR2025

Tweet Author

Janetbirdope

Tweet Content

#MTX in new #PMR?! RCT of #MTX was negative in early #PMR - no effect on #steroid #tapering ACR24 #1697 At #EULAR2025 👇 +RCT of #methotrexate in PMR <8wks #steroids #Rx MTX 25 mg/wk v #placebo N=64 ⬆️GC remission ✅80% v 46% ⬇️relapse w MTX 🤔 Abst0064 @RheumNow #EULAR2025

#EULAR2025 Opening Plenary C. Dejaco, the EULAR Congress chair presents the @eular_org congress in numbers: 4 days 300+

Tweet Author

AurelieRheumo

Tweet Content

#EULAR2025 Opening Plenary C. Dejaco, the EULAR Congress chair presents the @eular_org congress in numbers: 4 days 300+ Invited speakers 170+ Scientific sessions 40 Oral presentations 8 Poster tours 12000+ Attendees @RheumNow https://t.co/hX1ABtSio2

Links

https://x.com/AurelieRheumo/status/1932759920111231354/photo/1

11 June 2025

SLE Preview: advances to achieve deep B-cell depletion

The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus. Its main principle is to induce deep B-cell depletion, with the hope to reset the B-cell aberrant immunity for a sustained clinical remission. At EULAR 2025 in Barcelona, several advances of CAR-based therapies will be presented.

11 June 2025

Late-Onset Disease: Different Age, Different Rules?

We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related biology, comorbidity, and the biases that influence medical decision-making? Several abstracts presented at EULAR 2025 challenge us to reconsider how we diagnose and treat rheumatic disease in older adults.

#EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for

Tweet Author

Yuz6Yusof

Tweet Content

#EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for #Sjogren-Neuropathy. No superiority but clinical response was more complete & longer retention numerically favouring RTX. Support trial of BCDT in SjD @RheumNow https://t.co/87e6yFMRkk

Links

https://x.com/Yuz6Yusof/status/1932745900557816016/photo/1

Risk of #VTE in #rheumatoid #arthritis Is it better over last 25 yrs? 👎 Olmstead County population study of #RA Pt

Tweet Author

Janetbirdope

Tweet Content

Risk of #VTE in #rheumatoid #arthritis Is it better over last 25 yrs? 👎 Olmstead County population study of #RA Pts vs matched controls ⬆️VTE in RA ⬆️VTE w active RA But not change in rates of #DVT & #PE since 2000 Why? 🤔 Abst#OP0070 @rheumnow #EULAR2025 @eular_org https://t.co/eSyjfjVqtY

Links

https://x.com/Janetbirdope/status/1932571027982139799/photo/1

Topics

Treatment of MAS, or the bête noire in Still's disease, presented at the Plenary session by Peter Nigrovic #Plenary ro

#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources, #Easylupus is

Debuting Fishbowl sessions at #EULAR2025 🔄💊 Lively audience engaging session in A1 on how drug prices influence t

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

#MTX in new #PMR?! RCT of #MTX was negative in early #PMR - no effect on #steroid #tapering ACR24 #1697 At #EULAR2025

#EULAR2025 Opening Plenary C. Dejaco, the EULAR Congress chair presents the @eular_org congress in numbers: 4 days 300+

#EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for

Risk of #VTE in #rheumatoid #arthritis Is it better over last 25 yrs? 👎 Olmstead County population study of #RA Pt

Do you get our email newsletter?